A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients-Reference-Cited by-同舟云学术

A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients

Published:2024-04-01 Issue:3 Volume:22 Page:170-178
ISSN:1540-4196
Container-title:Metabolic Syndrome and Related Disorders
language:en
Short-container-title:Metabolic Syndrome and Related Disorders

Author:

Spasovski Goce¹,Rroji Merita²^ORCID,Hristov Goce³,Bushljetikj Oliver⁴,Spahia Nereida²,Rambabova Bushletikj Irena¹

Affiliation:

1. Department of Nephrology, Medical Faculty, University Sts. Cyril and Methodius, Skopje, North Macedonia.

2. Department of Nephrology, University of Medicine of Tirana, Tirana, Albania.

3. Department of Internal Medicine and Diabetes, General Public Hospital Strumica, Strumica, North Macedonia.

4. Department of Cardiology, Medical Faculty, University Sts. Cyril and Methodius, Skopje, North Macedonia.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/met.2023.0227

Reference54 articles.

1. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017

2. Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China

3. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

4. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

5. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review;Metabolism and Target Organ Damage;2024-04-07